Thus, based on the previous considerations, it is not difficult to understand how the BWRP-induced beneficial effects, as demonstrated in the present study and others, including a decrease in BCAAs (with no competition for LAT1) [110], APRI (aspartate transaminase to platelet ratio index, which is used as marker of NAFLD [3], and CRP (C-reactive protein, which grossly reveals systemic inflammation) [6,111], whether collectively or solely, can reduce the plasma levels of phenylalanine and tyrosine. Here, CRP is linked to metabolic dysfunction-associated steatotic liver disease.